DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Multicenter, Open-label, Single-use Autoinjector Convenience Study

Information source: EMD Serono
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Sclerosis

Intervention: Rebidose® (Device)

Phase: Phase 3

Status: Completed

Sponsored by: EMD Serono

Official(s) and/or principal investigator(s):
Fernando Dangond, MD, Study Director, Affiliation: EMD Serono

Summary

The purpose of this trial is to test the Single-Use Autoinjector for a) ease of use; b) multiple domains related to subject's acceptability and satisfaction, and c) reliability of the correct function for self-injection of Rebif« 44 mcg sc tiw in subjects with relapsing multiple sclerosis (RMS).

Clinical Details

Official title: A Twelve-week, Phase IIIb, Open-label, Single-arm, Multicenter Trial to Evaluate Ease of Use of a Ready-to-use, Single-use Autoinjector (SA) for Self-injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated With Rebif« 44mcg Subcutaneously (sc), Three Times a Week (Tiw)

Study design: Intervention Model: Single Group Assignment, Masking: Open Label

Primary outcome: Proportion of Relapsing Multiple Sclerosis (RMS) Subjects Rating the Single-use Autoinjector as 'Easy to Use' or 'Very Easy to Use' for Self-injection in a User Trial Questionnaire

Secondary outcome: Multiple Secondary Endpoints Were Assessed, Based on Questions From the User Trial Questionnaire Related to the Single-use Autoinjector Device Use-related Outcomes.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Male and female subjects, 18-65 years of age, inclusive, at the time of informed consent signature 2. RMS diagnosed according to the McDonald criteria 3. Currently receiving Rebif® 44mcg sc tiw using manual injections and/or Rebiject II autoinjector for greater than twelve weeks 4. Capable of self-injecting using the single-use autoinjector 5. Be willing and able to comply with the study procedures for the duration of the trial 6. Have given written informed consent and signed Health Insurance Portability and Accountability Act (HIPAA) Authorization before any study-related activities are carried out 7. Female subjects must not be either pregnant or breast-feeding and must lack childbearing potential Exclusion Criteria: 1. Have used any other injectable medications (i. e. for pain) on a regular basis during the week prior to Screening or throughout the duration of the trial (the administration of a single injection for treatment or prophylaxis of a condition unrelated to MS or Rebif® therapy (e. g., influenza or pneumococcus vaccination) will be acceptable) 2. Have received MS therapy other than Rebif® within twelve weeks prior to Screening or at any time during the trial (e. g., other disease modifying drugs, Rebif® New Formulation, combination therapy, immunomodulatory and/or immunosuppressive agents, including but not limited to any interferon, glatiramer acetate (Copolymer I), cyclophosphamide, cyclosporine, methotrexate, linomide, azathioprine, mitoxantrone, teriflunomide, laquinimod, cladribine, total lymphoid irradiation, anti-lymphocyte monoclonal antibody treatment (e. g. natalizumab, alemtuzumab/Campath, anti- CD4), Intravenous immunoglobulin (IVIg), cytokines or anti-cytokine therapy) and telbivudine 3. Have inadequate liver function, defined by a alanine aminotransferase (ALT) > 2. 5x upper limit of normal (ULN), or alkaline phosphatase > 2. 5x ULN, or total bilirubin > 2. 5x ULN 4. Have inadequate bone marrow reserve, defined as a total white blood cell count < 3. 0x 109/L, platelet count < 75x109/L, haemoglobin < 100g/L 5. Have complete transverse myelitis or bilateral optic neuritis 6. Have a history of alcohol or drug abuse 7. Have thyroid dysfunction 8. Have moderate to severe renal impairment 9. Have a major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol 10. Have a history of seizures not adequately controlled by treatment 11. Have serious or acute cardiac disease, such as uncontrolled dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure 12. Have, in the opinion of the investigator, any visual, physical or cognitive impairment that would preclude the subject from self-injecting with the single-use autoinjector 13. Have a known hypersensitivity or allergy to interferon-beta or any of the excipients 14. Have participated in another clinical trial within the past thirty days 15. Are pregnant or attempting to conceive

Locations and Contacts

EMD Serono, Inc., Rockland, Massachusetts 02370, United States
Additional Information

Starting date: October 2009
Last updated: August 2, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017